An interventional study of SUPOL and Dietary Pattern: MeDi in Mild Cognitive Impairment, sponsored by Aristotle University Of Thessaloniki. Recruiting at 2 sites in Greece. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Aristotle University Of Thessaloniki · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki — 4 open to participants now, 5 under way, none of them phase 3. Cognitive Dysfunction · Aristotle University Of Thessaloniki.
Among the 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 9th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →4 of the 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki are open now, in 1 country. Recruiting first, the newest first:
Aristotle University Of Thessaloniki · Sites in Greece
Aristotle University Of Thessaloniki · Sites in Greece
Ages 18+ · Healthy volunteers
Aristotle University Of Thessaloniki · Sites in Greece
Ages 55–85 · Healthy volunteers
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 114 across the 10 interventional studies, 175 across the 2 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Aristotle University Of Thessaloniki is the lead sponsor of 282 studies on the registry; 55 are open to participants now.
2 of the studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07844850Aristotle University Of ThessalonikiBiomarkers as Prognostic Factors of Silent, Cerebral Infarctions in Patients Undergoing High-thromboembolic-risk Transcatheter Interventions | 2027-05-01 |
| NCT07289061Aristotle University Of ThessalonikiPositive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Cognitive Dysfunction by Aristotle University Of Thessaloniki, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BACKGROUND: Mild cognitive impairment (MCI) constitutes a form of preclinical dementia and characterizes a cognitive decline that exceeds what is expected for one's age and education status, but at the same time does not fulfill the criteria for dementia. MCI is considered a prodromal stage of Alzheimer's disease (AD) and the progression to this neurodegenerative disease, renders the patients heavily dependent on their relatives and the society, which creates a huge psychological and financial burden, since no effective treatment exists for MCI and AD to this day. Mediterranean diet (MeDi) displays beneficial effects on the cognitive function of both healthy individuals and cognitive impaired patients. High Phenolic Early Harvest Extra Virgin Olive Oil (HP-EH-EVOO) is a natural product that contains high concentrations of the substance Oleocanthal (OLC), while at the same time it has been shown to exert beneficial properties on the cognitive function of cognitive impaired individuals, as well as on the slowing down of the decline of cognitive function.
AIM: The main hypothesis that will be evaluated is whether the combined approach of the MeDi pattern and the concurrent intervention with the administration in a capsule form of the supplement containing olive oil polyphenols with the main substance being Oleocanthal (SUPOL), could constitute a considerable strategy of management of MCI patients.
Study Type: Investigational Study Design, Allocantion: Randomized Intervention Model, Parallel Assignment Masking: Double Blind (Subject, Outcome Assessor - Investigator) on Supplement, Primary Purpose: Prevention.
OBJECTIVE OF THE TRIAL: To evaluate the efficacy of the combined approach of the MeDi pattern and the concurrent SUPOL compared to the MeDi diet pattern in combination with placebo on the change in cognition and function in subjects with MCI.
STUDY DESIGN: The study is designed as a 2x2 quasi-factorial design, which combines the characteristics of a prospective cohort study regarding dietary patterns and a randomized, placebo-controlled, 4-parallel-group clinical trial, double-blinded with respect to the dietary supplement.
PARTICIPANTS: Participants upon enrollment will be classified into two distinct cohorts based on their level of adherence to the MeDi (high and moderate adherence). The recruitment of N=200 participants with MCI is planned, who will initially be stratified into two strata: high adherence to the MeDi (n=100) and moderate adherence to the MeDi (n=100). Subsequently, participants within each cohort will be randomized in a 1:1 ratio to receive either SUPOL or placebo, creating 4 groups of n=50 individuals:
The assessment and grading of participants' adherence to the MeDi at baseline will be performed using the MedDietScore. Participants will be classified as follows:
DURATION: The duration of the intervention will be 12 months, while the neuropsychological assessment and laboratory testing will be performed at baseline, after the end of the intervention at 12 months and at 18 months (6 months after the completion of the intervention). The total study duration will be 18 months.
LOCATION: The study will be conducted in Thessaloniki and will recruit patients having diagnosed with MCI from the outpatient clinic 1st Neurological Clinic of the General University Hospital "AHEPA" (AHEPA) and the Greek Association of Alzheimer's Disease and Related Disorders (Alzheimer Hellas).
SCREENING - RANDOMIZATION - BASELINE (Visit 1): Patient eligibility will be determined during Visit 1. A protocol eligibility form will be completed for each patient and reviewed by the Principal Investigator (PI) approval prior to participation in the study. If eligibility is reached, baseline assessments, as well as randomization for group allocation will take place.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in this study only if all the following criteria apply:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical conditions
Imaging, Vital Signs, Laboratory Tests and Physical Examinations
Prior or Concomitant Therapy
Prior or Concurrent Clinical Study Experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 participants with high adherence to the MeDi pattern will receive SUPOL for 12 months.
Dietary Supplement: SUPOL · Other: Dietary Pattern: MeDi
50 participants with high adherence to the MeDi pattern will receive placebo for 12 months.
Other: Dietary Pattern: MeDi
50 participants with medium adherence to the MeDi pattern will receive SUPOL for 12 months.
Dietary Supplement: SUPOL
50 participants with medium adherence to the MeDi pattern will receive placebo for 12 months.
Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
High Adherance to MeDi pattern to be followed for 12 months.
ADAS-Cog - Measurement to Assess the Severity of Cognitive Impairment
Alzheimer's Disease Assessment Scale - Cognitive Subscale - 13 (ADAS-Cog-13) neuropsychological assessment scale scores ranges from 0 to 85, with greater scores showing a more significant cognitive impairment
Time frame: Baseline (Day 1) to 12 months
MMSE - Measurement to Assess and Evaluate Cogntive Function
Mini-Mental State Examination (MMSE) score ranges range from 0 to 30 and individuals will lower MMSE scores show greater cognitive impairment
Time frame: Baseline (Day 1) to 12 months
MoCA - Measurement to Assess Cognitive Abilities
Montreal Cognitive Assessment (MoCA) total score ranges from 0 to 30 and lower scores indicating greater impairment
Time frame: Baseline (Day 1) to 12 months
ADCS-ADL-MCI - Measurement to Assess and Evaluate the Performance in Different Activities of Daily Living
Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) MCI scale score ranges from 0 to 53, with poorer scores representing a more significant cognitive impairment
Time frame: Baseline (Day 1) to 12 months
CDR-SB - Measurement to Assess the Severity of the Disease and the Progression of the Disease
Clinical Dementia Rating Sum of Boxes (CDR-SB) total score ranges from 0 to 18, with greater scores corresponding to more significant impairment
Time frame: Baseline (Day 1) to 12 months
CDR - Measurement of Time to Progression to Dementia
Clinical Dementia Rating (CDR) global score ranges from 0 to 3, with the higher score corrisponding to severe dementia and the time to progression to dementia will be measured in weeks (unit)
Time frame: Baseline (Day 1) to 12 months
GDS - Measurement to Identify Depression in the Elderly
Geriatric Depression Scale (GDS) total score ranges from 0 to 30, with the classification of severity to be: (a) normal 0-9, (b) mild depression 10-19 and (c) severe depression 20-30
Time frame: Baseline (Day 1) to 12 months
C-SSRS - Measurement to Determine the Potential Risk for Suicide
"The Columbia-Suicide Severity Rating Scale (C-SSRS) Intensity of Ideation score ranges from 0 to 25, with higher numbers indicating more intense suicidal ideation
Time frame: Baseline (Day 1) to 12 months
TEAEs - Measurment of Number of Treatment Emergent Adverse Events
Number of treatment emergent adverse events (TEAEs) are measured in number of events from baseline
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in the Vital Signs
Number of participants with change from baseline in blood pressure (measured in mmHg) will be assessed
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in the Vital Signs
Number of participants with change in pulse rate (heart beats per minute) will be assessed
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in Physical Examination
Number of participants with change from baseline in physical examination will be evaluated
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in Neurological Examination
Number of participants with change from baseline on neurological examination will be evaluated
Time frame: Baseline (Day 1) to 12 months
Measurment of Change in Clinical Laboratory Tests
Number of participants with change from baseline in biochemical test will be evaluated
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in Clinical Laboratory Tests
Number of participants with change from baseline in haematological test wiil be evaluated
Time frame: Baseline (Day 1) to 12 months
Measurment of Change in Plasma Aβ1-42
Change in mean values of beta-amyloid 1-42 protein (Aβ1-42) plasma concentration
Time frame: Baseline (Day 1) to 12 months
Measurment of Change in Plasma Aβ1-40
Change in mean values of beta-amyloid 1-40 protein (Aβ1-40) plasma concentration
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in the Aβ1-42/Aβ1-40 Plasma Ratio
Change in the Amyloid-β1-42/Amyloid-β1-40 (Aβ1-42/Aβ1-40) ration in plasma levels
Time frame: Baseline (Day 1) to 12 months
Measurment of Change in Plasma pTau-181
Change in mean values of phosphorylated Tau-181 protein (pTau-181) plasma concentration
Time frame: Baseline (Day 1) to 12 months
Measurment of Change in Plasma pTau-217
Change in mean values of phosphorylated Tau-217 protein (pTau-217) plasma concentration
Time frame: Baseline (Day 1) to 12 months
Measurment of Change in Plasma GFAP
Change in mean values of Glial Fibrillary Acidic Protein (GFAP) plasma concentration
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in Plasma IL-1β
Change in mean value of Inteleukin-1β (IL-1β) plasma levels
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in Plasma IL-6
Change in mean value of Inteleukin-6 (IL-6) plasma levels
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in Plasma CRP
Change in mean value of C-Reactive Protein (CRP) plasma levels
Time frame: Baseline (Day 1) to 12 months
Measurement of Change in Gut Microbiota Composition
Change in gut microbiome alpha-diversity (α-diversity) and beta-diversity (β-diversity)
Time frame: Baseline (Day 1) to 12 months
Measurment of Change in Gut Microbiome Metabolites
Change in the gut microbiome short chain fatty acids (SCFAs) and medium chain fatty acids (MCFAs) concentration
Time frame: Baseline (Day 1) to 12 months
Plan to share: No — No plans to share data with other researchers
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Sep 2029, 55 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 55 months is above that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Nov 2024 → Jan 2025, primary completion Apr 2026 → Sep 2029 and completion Nov 2026 → Nov 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aristotle University Of Thessaloniki →